NeurAxis, Inc. (NRXS) News
Follow NeurAxis, Inc. (NRXS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 7 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
NeurAxis, Inc. (NRXS) Appoints Chief Commercial Officer
NeurAxis appointed Craig Blanchard as Chief Commercial Officer to lead sales and marketing as it plans to expand its commercial organization and covered lives.Material DetailsContext by AI AnalystThis is an early-to-mid
NEWS | Sep 29, 2026, 11:09 AM UTC
L
NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer
CARMEL, Ind., Sept. 29, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating con
NEWS | Sep 29, 2026, 11:08 AM UTC
L
NRXS - NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered Lives
NRXS - NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered Lives
NEWS | Sep 16, 2026, 01:00 PM UTC
L
NRXS - NeurAxis to Participate in the Lytham Partners Fall 2026 Investor Conference
NRXS - NeurAxis to Participate in the Lytham Partners Fall 2026 Investor Conference
NEWS | Sep 16, 2026, 11:00 AM UTC
L
NRXS: Expanding insurance coverage and sales force set the stage for rapid revenue growth in 2026-2027
The conference highlighted a med tech company’s rapid growth in neuromodulation therapies for GI disorders, driven by strong clinical evidence, expanding insurance coverage, and disciplined execution. With a large addres
NEWS | Sep 15, 2026, 02:35 PM UTC
L
NRXS: Strong insurance coverage and clinical data position the company for rapid growth through 2027
The conference featured a med tech company pioneering neuromodulation therapies for GI disorders, with strong insurance coverage, robust clinical evidence, and rapid revenue growth. Expansion of payer coverage and sales
EARNINGS | Sep 15, 2026, 01:55 PM UTC
M
NeurAxis Expands Payer Coverage
NeurAxis expands payer coverage with new policies
EQUITY | Aug 04, 2026, 11:00 AM UTC